GlassScriptPhysician profile
Sandra M Kochaon
NPI 1336470871
$6,369.98
in general payments reported to CMS, 2019-2025
35 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $882 · 2022: $900 · 2023: $1,274 · 2024: $1,720 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,564 · Travel and Lodging: $15.23 · Education: $8.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,563.63 |
| Travel and Lodging | $15.23 |
| Education | $8.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,786.74 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $675.00 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $653.11 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $560.79 | 2021-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.88 | 2021-2024 | Jardiance |
| Dexcom, INC. | $345.36 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $297.98 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.24 | 2025 | Caplyta |
| Corcept Therapeutics | $167.37 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $122.99 | 2024 | Inspire |
| Pfizer INC. | $94.63 | 2021-2025 | |
| Gilead Sciences, INC. | $72.02 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $71.34 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $67.42 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $62.09 | 2021-2024 | Proclaim |
| Kowa Pharmaceuticals America, INC. | $60.81 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $58.51 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.84 | 2024-2025 | Xifaxan |
| Amarin Pharma, INC. | $55.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $50.52 | 2021-2025 | |
| Astellas Pharma US INC | $47.22 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $46.26 | 2024 | Gvoke Hypopen |
| Teleflex LLC | $36.30 | 2025 | Urolift |
| Glaxosmithkline, LLC. | $30.85 | 2024 | Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $28.44 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.07 | 2023 | |
| Mallinckrodt Hospital Products INC. | $21.88 | 2021 | |
| Horizon Therapeutics Plc | $21.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.28 | 2021 | |
| Eisai INC. | $17.71 | 2021 | |
| Philips North America LLC | $17.44 | 2023 | |
| Scilex Pharmaceuticals INC. | $15.42 | 2024 | |
| Evoke Pharma, INC. | $12.02 | 2022 | |
| Ibsa Pharma INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Kochaon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.